Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
245 results
000248 - Evaluation of the tolerability of the administration of subcutaneous immunotherapy in a cluster schedule, in patients with rhinoconjunctivitis and/or asthma with sensitization to Olea europaea with or without sensitization to grasses
100057 - Specific IgE molecular sensitization pattern of House dust mite allergen-components by Component Resolved Diagnosis [CRD] in 318 patients of allergic diseases [Respiratory allergy [168], Food allergy [80], Atopic dermatitis [70]
100629 - Asthma outcomes in young adults completed sublingual immunotherapy in adolescence
100631 - Long-term post treatment benefits of house dust mites sublingual immunotherapy in polysensitized children
D1.149 - Murine IgG1 increased y subcutaneous immunotherapy suppressed development of allergic asthma
D1.150 - Study design for the saFety assessment of an Accelerated up-dosing scheme using one Strength of a native house dust mite allergen extract for subcutaneous immunoTherapy in children with allergic asthma in China (FAST II study)
D1.152 - Incidence of patients who needed to change their allergy immunotherapy product specific to mites or pollens in Spanish allergy unitsIncidence of switching specific allergic immunotherapy products in Spanish allergy units
D1.153 - Protocol for a randomized, 5-arm study to evaluate the combination of omalizumab and allergen immunotherapy in patients with asthma due to house dust mites
D1.154 - Safety of ultra-rush immunotherapy starting protocol with the molecular extract Diater Alt a 1 mol mix
D1.155 - Alterations in B cell memory induced by house dust mite allergen immunotherapy
D1.156 - Early Immunologic Parameters Predicting Response to Sublingual Immunotherapy in Allergic Rhinitis Patients
D1.157 - Type II Cytokine-Mediated Regulation of Alarmin Receptors in B Cells: Implications for Eosinophilic Esophagitis
D1.159 - The successful resolve of nasal polyps in patient with dupilumab treatment
D1.162 - Selecting the right immunotherapy for Vespa velutina nigrithorax anaphylaxis: does one treatment fits all?
D3.170 - Effectiveness and Safety Study of Subcutaneous Immunotherapy for Respiratory Allergy to Dermatophagoides and Lepidoglyphus Destructor
D3.178 - Efficacy of Index of reactivity (IR) liquid sublingual immunotherapy in allergic rhinoconjunctivitis: A systematic review and meta-analysis of randomised studies
D3.179 - Safety of 300IR liquid sublingual immunotherapy of cat allergen extract for respiratory allergy to cat dander: a post-marketing experience
D3.180 - Good patient adherence to sublingual immunotherapy for allergic rhinitis can be achieved, when ENT-physicians collaborate with pharmacies in a straightforward adherence programme
D3.182 - Health Economic Evaluation of 5-Grass Pollen Sublingual ImmunotherapyTablets for Grass Pollen-Induced Allergic Rhinitis in Finland, Norway and Sweden
D3.183 - Reduction in Healthcare Resource Utilization in patients treated with 300 IR liquid SLIT: Real-World Evidence from Spain and Italy
Pagination
Current page
1
Page
2
Page
3
Page
4
Page
5
Page
6
Page
7
Page
8
Page
9
…
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download